Randomised Trials in prevention of thrombotic complications during PCI

Randomised Trials in prevention of thrombotic complications during PCI

On this page you will find a list of randomised trials in prevention of thrombotic complications during PCI, published in some of the world's top cardiology and interventional cardiology journals.

10.1 - DURATION DUAL ANTIPLATELET TREATMENT

  • 6-month vs 12-month dual antiplatelet Rx: EXCELLENT
  • Short- vs long-term dual-antiplatelet therapy: PRODIGY
  • Duration of dual antiplatelet Rx with clopidogrel: PRODIGY
  • Three vs twelve months of dual antiplatelet therapy: OPTIMIZE
  • Optimal duration antiplatelet treatment: DES LATE
  • Dual antiplatelet treatment beyond 1-year DES: ARCTIC-Interruption
  • 12 or 30 months of dual antiplatelet treatment: DAPT study
  • Second-generation DES: 6- vs 12-month dual antiplatelet therapy: SECURITY
  • Antiplatelet duration following BMS implantation: DAPT
  • DAPT 6 - versus 24 month therapy after DES in non-resistant aspirin patients: ITALIC - Final Results (Added in December 2017)
  • 6- vs 12-month DAPT after EES implantation: ITALIC
  • 6- vs 12-month clopidogrel treatment post PCI: ISAR-SAFE
  • DAPT: 6 vs 18 months therapy NIPPON STUDY (Added in December 2017)
  • 6-month versus 12-month dual-antiplatelet treatment: IVUS-XPL trial
  • Stopping or continuing clopidogrel 12 months after DES: OPTIDUAL trial
  • Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: TROPICAL-ACS (Added in December 2017)

10.2 - CLOPIDOGREL / ABCIXIMAB

  • Clopidogrel with or without aspirin: WOEST
  • Triple therapy in patients requiring oral anticogulation after DES ISAR-Triple trial

10.3 - BIVALIRUDIN

  • Abciximab/heparin vs bivalirudin for NSTEMI: ISAR-REACT 4 trial – 1 year
  • Bivalirudin vs unfractioned heparin in ACS: MATRIX
  • Bivalirudin vs Heparin in acute myocardial infarction: VALIDATE-SWEDEHEART (Added in December 2017)
  • Bivalirudin vs heparin alone or heparin and tirofiban during PPCI BRIGHT-Trial

10.4 - CANGRELOR

  • Cangrelor during PCI: CHAMPION PHOENIX

10.5 - PRASUGREL

  • Pre-treatment prasugrel for NSTEMI: ACCOAST
  • Prasugrel pre-treatment strategy PCI for NSTEMI: ACCOAST-PCI study
  • TRIGGER-PCI

10.6 - CILOSTAZOL

  • Adjunctive cilostazol vs double-dose clopidogrel after DES: HOST-ASSURE

10.7 - OTAMIXABAN

  • Otamixaban (direct factor Xa inhibitor) in non-ST-segment ACS: TAO trial

10.8 - RANOLAZINE

  • Ranolazine after incomplete PCI revascularisation: RIVER-PCI

10.9 - PLATELET REACTIVITY

  • Adjustment antiplatelet therapy: ARCTIC study
  • High on-treatment platelet reactivity: ARCTIC study
  • Platelet function monitoring to adjust antiplatelet therapy: ANTARCTIC-trial

Access these randomised trials here

Sponsored by

Biotronik